ReviewJournal of personalized medicine2022

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease.

Panagiotis I Georgianos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.